Entrada Therapeutics, Inc.
NASDAQ: TRDA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dipal Doshi
- Employees
- 183
- Headquarters
- Boston, United States
- IPO year
- 2021
- Market cap
- $292.7M
- Website
- https://www.entradatx.com
Loading TRDA…
Loading profile data…Frequently asked questions about TRDA
What does Entrada Therapeutics, Inc. (TRDA) do?
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody,...
Where does TRDA trade?
Entrada Therapeutics, Inc. (TRDA) trades on the NASDAQ Global Market.
What sector is TRDA in?
Entrada Therapeutics, Inc. (TRDA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Entrada Therapeutics, Inc.?
Dipal Doshi is the chief executive officer of Entrada Therapeutics, Inc. (TRDA).
Where is Entrada Therapeutics, Inc. headquartered?
Entrada Therapeutics, Inc. is headquartered in United States.
Does TRDA pay a dividend?
Entrada Therapeutics, Inc. (TRDA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did TRDA go public?
Entrada Therapeutics, Inc. (TRDA) completed its initial public offering in 2021.